microRNA Expression in Renal Cell Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Sun Yat-sen University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT00743054
First received: August 27, 2008
Last updated: March 9, 2009
Last verified: March 2009
  Purpose

In this study, renal cell carcinoma (RCC) related miRNA and the target genes of related miRNA will be examined in order to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.


Condition
Carcinoma, Renal Cell

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: microRNA Expression in Renal Cell Carcinoma

Resource links provided by NLM:


Further study details as provided by Sun Yat-sen University:

Biospecimen Retention:   Samples With DNA

The tumor tissues and tumor adjacent tissues will be collected when patients receive renal cell carcinoma resection.


Estimated Enrollment: 50
Study Start Date: July 2008
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Due to the lack of specific indicators for the early diagnosis of RCC, the RCC patients often have distant metastasis when diagnosed and their five-year survival rate is much low. Therefore, the biological markers of RCC are needed for early detection, early treatment and improvement of the survival rate of RCC patients.

MiRNA and tumor are closely related. MiRNA can control the important cancer-related genes and participate in the tumor cell proliferation, apoptosis, invasion and angiogenesis.

In this study, renal cell carcinoma(RCC) related miRNA and the target genes of related miRNA will be examined,and the relationship between RCC related miRNA and the RCC pathological types, TNM (tumor-nodes-metastasis) stages and prognosis will be analyzed. The purpose of this study is to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inpatients in the department of Urology of 1st Affiliated Hospital, Sun Yat-Sen University

Criteria

Inclusion Criteria:

  • Patients with primary renal cell carcinoma.
  • Subjects who agree to participate in the study and sign the informed consent.

Exclusion Criteria:

  • Patients with secondary renal cell carcinoma.
  • Subjects who refuse to participate in the study and sign the informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00743054

Contacts
Contact: Haiping Mao, M.D.& Ph.D. 8620-87755766 haipingmao@126.com

Locations
China, Guangdong
The 1st Affiliated Hospital, Sun Yet-sen University Recruiting
GuangZhou, Guangdong, China, 510080
Contact: Xueqing Yu, M.D. & Ph.D.    8620-87766335    yuxq@mail.sysu.edu.cn   
Contact: Haiping Mao, M.D. & Ph.D.    8620-87755766 ext 8143    haipingmao@126.com   
Principal Investigator: Xueqing Yu, M.D.& Ph.D.         
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Principal Investigator: Xueqing Yu, M.D. & Ph.D. 1st Affiliated Hospital, Sun Yat-Sen University
  More Information

No publications provided

Responsible Party: Xueqing Yu/Director, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT00743054     History of Changes
Other Study ID Numbers: SYSU-MiRNARCC
Study First Received: August 27, 2008
Last Updated: March 9, 2009
Health Authority: China: Food and Drug Administration

Keywords provided by Sun Yat-sen University:
Carcinoma, Renal Cell
MicroRNAs

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on August 18, 2014